{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:38:19Z","timestamp":1786995499275,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA035813"],"award-info":[{"award-number":["R01DA035813"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.pbb.2020.173043","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T22:19:02Z","timestamp":1601763542000},"page":"173043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine by low-dose galantamine in rats"],"prefix":"10.1016","volume":"199","author":[{"given":"Britta","family":"Hahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"Reneski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcom","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg I.","family":"Elmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna F.R.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2020.173043_bb0005","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.2741\/2424","article-title":"Evidence for a role of nicotinic acetylcholine receptors in schizophrenia","volume":"12","author":"Adams","year":"2007","journal-title":"Front. Biosci."},{"issue":"35","key":"10.1016\/j.pbb.2020.173043_bb0010","doi-asserted-by":"crossref","first-page":"13220","DOI":"10.1073\/pnas.0605370103","article-title":"Effective countermeasure against poisoning by organophosphorus insecticides and nerve agents","volume":"103","author":"Albuquerque","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2020.173043_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijpsycho.2019.02.005","article-title":"Combining CDP-choline and galantamine, an optimized alpha7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia","volume":"145","author":"Choueiry","year":"2019","journal-title":"Int. J. Psychophysiol."},{"key":"10.1016\/j.pbb.2020.173043_bb0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.20982\/tqmp.01.1.p042","article-title":"Confidence intervals in within-subject designs: a simpler solution to Loftus and Masson\u2019s method","volume":"1","author":"Cousineau","year":"2007","journal-title":"Tutor. Quant. Methods Psychol."},{"issue":"4","key":"10.1016\/j.pbb.2020.173043_bb0025","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JAD-2007-11411","article-title":"Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer\u2019s neuropathology","volume":"11","author":"Coyle","year":"2007","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.pbb.2020.173043_bb0030","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1124\/mol.64.5.1217","article-title":"The allosteric potentiation of nicotinic acetylcholine receptors by galantamine is transduced into cellular responses in neurons: Ca2+ signals and neurotransmitter release","volume":"64","author":"Dajas-Bailador","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2020.173043_bb0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2013.05.023","article-title":"Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy","volume":"148","author":"Deutsch","year":"2013","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.pbb.2020.173043_bb0040","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/0269881117691590","article-title":"First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288","volume":"31","author":"Gee","year":"2017","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pbb.2020.173043_bb0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2004.11.042","article-title":"Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits","volume":"1033","author":"Geerts","year":"2005","journal-title":"Brain Res."},{"issue":"3\u20134","key":"10.1016\/j.pbb.2020.173043_bb0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0928-4257(98)80034-X","article-title":"Cholinergic foundations of Alzheimer\u2019s disease therapy","volume":"92","author":"Giacobini","year":"1998","journal-title":"J. Physiol. Paris"},{"issue":"3","key":"10.1016\/j.pbb.2020.173043_bb0055","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/mol.107.035410","article-title":"Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes","volume":"72","author":"Gronlien","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.pbb.2020.173043_bb0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-13665-3_5","article-title":"Nicotinic receptors and attention","volume":"23","author":"Hahn","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2020.173043_bb0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00213-004-1969-5","article-title":"Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists","volume":"177","author":"Hahn","year":"2005","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2020.173043_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00213-002-1005-6","article-title":"Nicotine-induced enhancement of attention in the five-choice serial reaction time task: the influence of task demands","volume":"162","author":"Hahn","year":"2002","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pbb.2020.173043_bb0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0028-3908(03)00099-6","article-title":"Attentional effects of nicotinic agonists in rats","volume":"44","author":"Hahn","year":"2003","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2020.173043_bb0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-011-2258-8","article-title":"Selective nicotinic receptor antagonists: effects on attention and nicotine-induced attentional enhancement","volume":"217","author":"Hahn","year":"2011","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pbb.2020.173043_bb0085","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00213-016-4236-7","article-title":"Strain dependency of the effects of nicotine and mecamylamine in a rat model of attention","volume":"233","author":"Hahn","year":"2016","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2020.173043_bb0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00213-017-4780-9","article-title":"Prenatal kynurenine treatment in rats causes schizophrenia-like broad monitoring deficits in adulthood","volume":"235","author":"Hahn","year":"2018","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pbb.2020.173043_bb0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00213-019-05363-4","article-title":"Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine in healthy human subjects","volume":"237","author":"Hahn","year":"2020","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pbb.2020.173043_bb0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156802610790410983","article-title":"Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer\u2019s disease","volume":"10","author":"Haydar","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"issue":"4","key":"10.1016\/j.pbb.2020.173043_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00213-010-1848-1","article-title":"Meta-analysis of the acute effects of nicotine and smoking on human performance","volume":"210","author":"Heishman","year":"2010","journal-title":"Psychopharmacology"},{"issue":"5","key":"10.1016\/j.pbb.2020.173043_bb0110","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1601-183X.2011.00689.x","article-title":"A CHRNA5 allele related to nicotine addiction and schizophrenia","volume":"10","author":"Hong","year":"2011","journal-title":"Genes Brain Behav."},{"issue":"1","key":"10.1016\/j.pbb.2020.173043_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pharmthera.2012.08.012","article-title":"Nicotinic acetylcholine receptors: from basic science to therapeutics","volume":"137","author":"Hurst","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.pbb.2020.173043_bb0120","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00259-010-1644-5","article-title":"Decreased cerebral alpha4beta2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer\u2019s disease assessed with positron emission tomography","volume":"38","author":"Kendziorra","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"10.1016\/j.pbb.2020.173043_bb0125","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/1568007023339102","article-title":"Nicotinic treatment for cognitive dysfunction","volume":"1","author":"Levin","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"10.1016\/j.pbb.2020.173043_bb2005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002130050671","article-title":"Nicotine enhances sustained attention in the rat under specific task conditions","volume":"138","author":"Mirza","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2020.173043_bb0130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.20982\/tqmp.04.2.p061","article-title":"Confidence intervals from normalized data: a correction of Cousineau","volume":"4","author":"Morey","year":"2008","journal-title":"Tutor. Quant. Methods Psychol."},{"issue":"8","key":"10.1016\/j.pbb.2020.173043_bb0135","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bcp.2011.06.008","article-title":"Functional brain imaging of nicotinic effects on higher cognitive processes","volume":"82","author":"Newhouse","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"1\u20133","key":"10.1016\/j.pbb.2020.173043_bb0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(00)00064-9","article-title":"Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases","volume":"393","author":"Perry","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.pbb.2020.173043_bb0145","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/npp.2010.12","article-title":"Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers","volume":"35","author":"Petrovsky","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pbb.2020.173043_bb0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2174\/138161210790170166","article-title":"Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists","volume":"16","author":"Radek","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.pbb.2020.173043_bb0155","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","article-title":"Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors","volume":"305","author":"Samochocki","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.pbb.2020.173043_bb0160","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0026-895X(24)12219-5","article-title":"The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system","volume":"61","author":"Santos","year":"2002","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2020.173043_bb0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.npp.1301087","article-title":"Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors","volume":"32","author":"Schilstrom","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pbb.2020.173043_bb0170","first-page":"1096","article-title":"Nicotinic acetylcholine receptor system and neuropsychiatric disorders","volume":"7","author":"Singh","year":"2004","journal-title":"IDrugs"},{"issue":"3","key":"10.1016\/j.pbb.2020.173043_bb0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00213-012-2763-4","article-title":"Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report","volume":"224","author":"Sofuoglu","year":"2012","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.pbb.2020.173043_bb0180","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","article-title":"An update on the pharmacology of galantamine","volume":"16","author":"Villarroya","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.pbb.2020.173043_bb0185","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pbb.2011.03.022","article-title":"Drug targets for cognitive enhancement in neuropsychiatric disorders","volume":"99","author":"Wallace","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.pbb.2020.173043_bb0190","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bcp.2011.05.001","article-title":"Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations","volume":"82","author":"Williams","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.pbb.2020.173043_bb0195","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/009127000204200907","article-title":"Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects","volume":"42","author":"Zhao","year":"2002","journal-title":"J. Clin. Pharmacol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720300320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720300320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:37:44Z","timestamp":1758775064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305720300320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"alternative-id":["S0091305720300320"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.173043","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for positive allosteric modulation of cognitive-enhancing effects of nicotine by low-dose galantamine in rats","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.173043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"173043"}}